Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Vancomycin for Primary CDI Prophylaxis
NCT02951702Phase 4Completed
- Sponsor
- St. Luke's Hospital
- Start
- Nov 2016
- Primary completion
- May 2017
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
A Phase 4 trial of vancomycin in Clostridioides difficile infection (CDI), sponsored by St. Luke's Hospital. Started Nov 2016; status: completed.
02
Drugs
vancomycin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02951702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02951702.